The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of short-duration chemoimmunotherapy plus radioimmunotherapy on response rates in relapsed follicular lymphoma: A U.K. NCRI Lymphoma Group Study, CR UK/07/038.
Timothy M Illidge
Consultant or Advisory Role - Bayer Schering Pharma; Roche/Genentech
Honoraria - Bayer Schering Pharma; Roche/Genentech
Research Funding - Schering Healthcare
Andrew T. Bates
Other Remuneration - Bayer Schering Pharma
Andrew John Davies
Consultant or Advisory Role - Roche
Honoraria - Roche
Ruth Pettengell
Other Remuneration - Roche
Barry Andrews
No relevant relationships to disclose
Louise Dent
No relevant relationships to disclose
Grace Hampson
No relevant relationships to disclose
Maureen Zivanovic
No relevant relationships to disclose
Eve Gallop-Evans
Consultant or Advisory Role - Roche
Honoraria - Roche
John A. Radford
Consultant or Advisory Role - Bayer Schering Pharma; Roche
Honoraria - Bayer Schering Pharma; Roche
Research Funding - Roche
Other Remuneration - Roche
Peter W. M. Johnson
Consultant or Advisory Role - Roche
Honoraria - Roche